Overview

Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status:
Recruiting

Trial end date:
2023-09-04

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab and determine a recommended Phase 2 dose (RP2D) in patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Vaccinex Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab